Publications by authors named "Michelle Erdmann"
Background: Omalizumab is a treatment option for pediatric and adult patients with moderate to severe allergic asthma poorly controlled with standard inhaled therapies. Clinical trials and observational studies have demonstrated the efficacy of omalizumab. There is limited real-world evidence on the characteristics and treatment patterns of Canadian asthma patients receiving omalizumab.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess how well postmenopausal women with osteoporosis continued using denosumab through a Canadian support program called ProVital, which offers reminders and education.
- A total of 1,676 women participated, with 81.6% continuing their treatment after 12 months and 59.1% after 24 months; factors like having private insurance and living in Quebec were linked to better persistence.
- Limitations included voluntary enrollment, which may lead to selection bias, and the absence of a control group for comparison.